| 查看: 387 | 回复: 1 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
cainiaodui新虫 (小有名气)
|
[求助]
翻译求助
|
||
| Although Notch inhibitors are still preclinical, the monoclonal VEGF antibody bevacizumab is clinically available and represents a potential for combination therapy. As discussed above, some tumors are responsive to VEGF inhibition, although others are unresponsive and become resistant over time.This is most likely due to compensation by other angiogenic pathways that maintain the tumor vasculature. In patients with metastatic breast cancer, treatment with anti-VEGF therapy did not show a statistically significant increase in overall survival benefit.However, combination anti-angiogenic therapy may be useful in overcoming this resistance. |
回复此楼» 猜你喜欢
职称评审没过，求安慰
已经有3人回复
-
垃圾破二本职称评审标准
已经有10人回复
-
聘U V热熔胶研究人员
已经有8人回复
-
投稿返修后收到这样的回复，还有希望吗
已经有8人回复
-
三无产品还有机会吗
已经有6人回复
-
博士申请都是内定的吗？
已经有14人回复
-
谈谈两天一夜的“延安行”
已经有13人回复
-
氨基封端PDMS和HDI反应快速固化
已经有11人回复
-
论文投稿求助
已经有4人回复
-
Applied Surface Science 这个期刊。有哪位虫友投过的能把word模板发给我参考一下嘛
已经有3人回复
RXMCDM
版主 (文坛精英)
- 翻译EPI: 530
- 应助: 401 (硕士)
- 贵宾: 1.908
- 金币: 38947.6
- 散金: 4908
- 红花: 88
- 沙发: 4
- 帖子: 11453
- 在线: 1355.6小时
- 虫号: 2739168
- 注册: 2013-10-20
- 性别: GG
- 专业: 一般管理理论与研究方法论
- 管辖: 论文翻译
2楼2014-04-26 20:53:46